Analyst firms · Piper Sandler · AMPH

Piper Sandler AMPH price target and rating history

Amphastar Pharmaceuticals Inc. (AMPH) · Health Care

Piper Sandler rates Amphastar Pharmaceuticals Inc. (AMPH) Neutral with a $36 price target, as of its latest action on Feb 4, 2025. It has published 3 rating actions on AMPH since January 2022, including 1 upgrade and 1 downgrade. Across 4 firms with a AMPH price target in the last 12 months, the median target is $21.

Current rating
Neutral
Price target
$36
Median target, all firms
$21
Actions on AMPH
3

Piper Sandler price target on AMPH

$36$32$282023202420252026
Piper Sandler price target on AMPH, each point a stated target, January 2022 to February 2025.

Every Piper Sandler rating on AMPH

How other firms rate AMPH

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BofA SecuritiesUnderperform$20Jun 29, 2026
Wells FargoEqual Weight$19May 14, 2026
NeedhamHoldMay 8, 2026
JefferiesHold$22Apr 21, 2026
BarclaysEqual Weight$30Dec 9, 2025

Questions about Piper Sandler and AMPH

What is Piper Sandler's price target for AMPH?
Piper Sandler's latest stated price target for Amphastar Pharmaceuticals Inc. (AMPH) is $36, from its action on Feb 4, 2025.
What is Piper Sandler's rating on AMPH?
Piper Sandler rates AMPH Neutral, a neutral rating, as of Feb 4, 2025.
When did Piper Sandler last change its view on AMPH?
On Feb 4, 2025, Piper Sandler downgrades to Neutral from Overweight, price target $66 to $36.
How does Piper Sandler's AMPH target compare with other analysts?
Across 4 firms with a AMPH price target in the last 12 months, the median target is $21.

More AMPH rating histories

All Piper Sandler ratingsAMPH news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.